347 reports of this reaction
2.6% of all CARIPRAZINE reports
#6 most reported adverse reaction
TARDIVE DYSKINESIA is the #6 most commonly reported adverse reaction for CARIPRAZINE, manufactured by Allergan, Inc.. There are 347 FDA adverse event reports linking CARIPRAZINE to TARDIVE DYSKINESIA. This represents approximately 2.6% of all 13,196 adverse event reports for this drug.
Patients taking CARIPRAZINE who experience tardive dyskinesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TARDIVE DYSKINESIA is a less commonly reported adverse event for CARIPRAZINE, but still significant enough to appear in the safety profile.
In addition to tardive dyskinesia, the following adverse reactions have been reported for CARIPRAZINE:
The following drugs have also been linked to tardive dyskinesia in FDA adverse event reports:
TARDIVE DYSKINESIA has been reported as an adverse event in 347 FDA reports for CARIPRAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TARDIVE DYSKINESIA accounts for approximately 2.6% of all adverse event reports for CARIPRAZINE, making it a notable side effect.
If you experience tardive dyskinesia while taking CARIPRAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.